The gene for catechol-O-methyltransferase (COMT) plays a key modulatory role in dopaminergic and noradrenergic neurotransmission. Recent evidence suggests that modafinil, like other stimulants, might act through the dopaminergic system. We have reported a sexual dimorphism and a strong effect of the COMT genotype on narcolepsy symptoms and hypothesized that response to modafinil treatment may be associated with the COMT genotype. Here we confirm that COMT genotype distribution between men and women narcoleptics is associated with response to modafinil. In addition, the optimal daily dose of modafinil is approximately 100 mg lower in women narcoleptics and lower in all narcoleptics with low activity COMT genotype. Our results suggest that a sexual dimorphism in COMT activity affects the response to modafinil and probably to other dopaminergic stimulants.
INTRODUCTION
Narcolepsy is a disabling neurological disorder characterized by two major symptoms, excessive daytime sleepiness and cataplexy (loss of muscle tone triggered by strong emotions). The implication of monoaminergic systems in the pathophysiology of narcolepsy is well established. 1 We recently reported that a common functional polymorphism of the COMT gene, which results in a 3-to 4-fold change in enzyme activity, had a sexual dimorphism and a strong effect on severity of narcolepsy symptoms. 2 Women narcoleptics with high COMT activity (HH genotype) felt asleep twice as fast as those with low COMT activity during the multiple sleep latency test while the opposite was true for men. These data strongly suggested a genetic link between narcolepsy and the dopaminergic/ noradrenergic systems.
Traditional stimulants such as amphetamine strongly promote wakefulness but have serious side effects that limit their clinical use to treat excessive daytime sleepiness. Modafinil (2-[(diphenylmethyl) sulfinyl] acetamide) is a novel compound, which has been shown to have an efficacy comparable to amphetaminelike stimulants without producing dependence and abuse. Modafinil has been used in narcolepsy treatment for over a decade in France and has recently been introduced in many other countries as the first choice treatment of pathological sleepiness. [3] [4] [5] [6] The exact mechanism of action of modafinil is not fully understood. Several studies suggested that modafinil and amphetamine promote wakefulness via different mechanisms of action. [7] [8] [9] [10] However, modafinil binds the dopamine transporter (DAT) with low affinity 11 and a recent study demonstrated that modafinil and amphetamine increase extracellular dopamine and DAT knockout mice are unresponsive to both compounds.
we have hypothesized that its functional genetic polymorphism might contribute to the response to dopaminergic stimulants. This may also explain why 10-20% of narcoleptics do not respond and up to 30% respond partially to modafinil.
3-6 Thus, we have analyzed the response of 84 narcoleptics to modafinil as a function of their COMT genotype.
RESULTS
Seventy-seven patients were classified as responders to modafinil (with 52 good responders and 25 moderate responders) and only seven as non-responders (Table 1) . Only one out of the seven non-responders was a woman (3.1% of women vs 11.5% of men). The gender as such did not affect the response to modafinil since 22 out of 32 (68.75%) women and 30 out of 52 (57.69%) men were good responders ( 2 ϭ 1.03, df ϭ 1, P Ͼ 0.3) whereas COMT genotype significantly affected the response to modafinil (good vs moderate ϩ non-responders: 2 ϭ 6.5, df ϭ 2, P Ͻ 0.04). Among HH genotypes, fewer narcoleptics were good responders (12 out of 28 or 42.86%) than moderate and non-responders (40 out of 56 or 71.43%; 2 ϭ 6.5, df ϭ 1, P Ͻ 0.02; OR ϭ 0.30, 95% CI ϭ 0.12-0.77). As in our previous study, 2 the distribution of COMT genotypes showed a significant difference between men and women narcoleptics ( Table 1, 2 ϭ 6.3, df ϭ 2, P Ͻ 0.05). Eleven out of 32 women (34.37%) and seven out of 52 men were LL (13.46%; 2 ϭ 5.1, df ϭ 1, P Ͻ 0.03). The COMT genotype distribution showed the same significant difference when patients were classified as modafinil responders (good ϩ moderate) and non-responders according to gender (Table 1, 2 ϭ 6.6, df ϭ 2, P Ͻ 0.04).
The optimal daily dose of modafinil differed significantly between gender. The mean daily dose in women was 262.50 Ϯ 16.65 mg, significantly lower than 343.34 Ϯ 16.17 mg in men (two-way ANOVA, factor gender F 1,71 ϭ 7.66, P Ͻ 0.008). Also the optimal daily dose was slightly affected by COMT genotype (two-way ANOVA, factor COMT genotype F 2,71 ϭ 2.87, P Ͻ 0.06). Patients with the LL genotype received less daily dose than those with the LH or HH genotype (LL ϭ 241 Ϯ 21.11 mg; LH ϭ 329.17 Ϯ 18.30 mg; HH ϭ 329.17 Ϯ 22.10 mg). No interaction was found between the optimal modafinil daily dose, the age of treatment onset, the response to treatment (good, moderate or no response), and the presence of previous treatment with amphetamine. When the previous or concomitant use of tricyclic antide- The Pharmacogenomics Journal pressants, selective serotonine reuptake inhibitors, or a combination of both was taken into account, the response rate as well as the optimal daily modafinil dose remained unchanged.
DISCUSSION
The most prominent finding of the present study is the significant association between COMT genotype distribution and the response to modafinil treatment. This result strengthens the involvement of dopaminergic metabolism in the mechanism of action of modafinil. The sexual dimorphism found for the COMT genotype in narcolepsy 2 is further extended to the response to modafinil. The optimal daily dose of modafinil significantly differs between gender with nearly 100 mg per day less in women. The distribution of the COMT genotype also slightly affects the optimal daily dose.
The COMT LL genotype corresponds to 3-4 times less activity of the enzyme (ie higher dopamine level) as compared to the HH genotype. Women narcoleptics present an even number of the three COMT genotypes, a distribution significantly different from male narcoleptics due to a lower frequency of the LL genotype in men. The response to modafinil treatment virtually parallels this genotype distribution, indicating that men and women narcoleptics do not respond to modafinil in the same way as a function of their COMT genotype. Because the number of men with LL genotype is lower than that for women, good responders are 11% lower in men than in women narcoleptics. However, men and women with low COMT enzyme activity have exactly the same rate of good response (71.43% and 72.73% in men and women, respectively), suggesting that independent of gender, increasing the dopaminergic transmission is more efficient when the activity of the enzyme is low (LL genotype), while only 35.30% of men and 54.54% of women narcoleptics with high COMT enzyme activity are good responders. This finding is corroborated by the fact that narcoleptics with low enzyme activity, and more so women narcoleptics, received a significantly lower effective daily dose of modafinil.
A limit of this study is the absence of modafinil serum concentration measurements. Although the test became recently available, 13 it is not used in clinical routine, and therefore has never been used in narcoleptics. Also, the serum modafinil level may not reflect regional brain concen-trations of active metabolites. Nevertheless, a recent pharmacokinetic study of modafinil indicated that young healthy women had a faster clearance rate than men and that the clearance rate of modafinil decreased with age in men.
14 A similar study in narcoleptics with concomitant evaluation of modafinil efficacy is therefore needed. Meanwhile since the frequency of the LL genotype (low enzyme activity) is found to be significantly higher in women narcoleptics in association with lower severity of excessive daytime sleepiness, 2 and the fact they take lower doses of modafinil, we suggest that women may have a higher steady dopaminergic tone than men narcoleptics. Note also that in the present study, neither the age of patients, nor the age of onset of the disease nor that of modafinil treatment affected the results. Additionally, other parameters such as the previous use of amphetamine-like drugs or present use of anticataplectic medication did not affect the response to modafinil, leaving the COMT genotype and gender as the best predictors. The fact that previous or current antidepressent treatment has no effect on modafinil response is of special interest. Modafinil has no inhibitory effect on any P450 enzymes, which have a high genetic polymorphism, except CYP2C19. 15 Although at least tricyclics affect CYP2C19 activity, there is little if any evidence of a gender difference in CYP2C19 activity. 16 Additionally, only 3-6% of Caucasians (less than five patients in our study) are poor metabolizers of CYP2C19 substrates. 17 Therefore we believe that CYP gene polymorphisms have little chance of representing a confounding factor.
The findings of this study constitute the first report of the use of pharmacogenetics in sleep disorders. The differences in daily dose between gender and COMT genotypes may help individualization of modafinil treatment and highlight the importance of understanding the genetic basis of variability in drug response. We believe that the present results warrant larger-scale well-controlled pharmacogenetic studies not only in narcolepsy but also in attention-deficit hyperactivity disorder and addiction to stimulants.
MATERIALS AND METHODS

Sample
The subjects were 84 out of the 97 previousely reported Caucasian narcoleptics 2 (52 men and 32 women, age range 14-80 years, mean age 48.21 Ϯ 19.25 years) treated with modafinil for typical narcolepsy (ie recurrent daytime sleep episodes and well-defined cataplexy). The mean age of narcolepsy onset was 20.16 Ϯ 10.74 years, the mean age of onset of modafinil treatment was 39.33 Ϯ 18.65 years, and the mean duration of modafinil treatment was 7.49 Ϯ 4.35 years. Patients received a minimum of 100 and a maximum of 600 mg daily dose of modafinil.
Forty-four patients received concurrently one or two anticataplectic drugs: clomipramine (n ϭ 21), fluoxetine (n ϭ 9), or a combination of both drugs (n ϭ 14). In addition, 23 patients had received amphetamine-like stimulants and 16 anticataplectic drugs before the introduction of modafinil.
The effect of modafinil on excessive daytime sleepiness www.nature.com/tpj was established on the basis of clinical investigation. The global clinical impression at optimal daily dose of modafinil (generally obtained after 2-4 clinic visits with readjustment of the dose during the first year of treatment) was classified as: 2 for good response (striking improvement to total reduction in excessive daytime sleepiness), 1 for moderate response (intermediate improvement), and 0 when no effect was observed. The mean optimal daily dose defined as the dose with maximum improvement of excessive daytime sleepiness was 307 Ϯ 109 mg. In order to minimize differences in the interpretation of data obtained from clinical charts, the same investigator (YD) pooled all data and was kept blind to COMT genotyping data.
Genotyping COMT genotypes were determined by RFLP analysis. A G to A substitution at codon 158 encoding a valine or methionine generates the polymorphism. The target sequence was PCR amplified and the product was digested by the restriction enzyme Nlalll and electrophoresed in a 8% polyacrylamide gel to detect the two alleles (Met158 or L for low activity 64-bp allele vs Val158 or H for high activity 91-bp allele) as previously reported. 
Statistical Analysis
Genotype frequencies were compared according to treatment response and gender by means of 2 probability test. A two-way analysis of variance (ANOVA) was used to assess the effect of genotype and gender on optimal daily dose.
